ABSTRACT:

Bosentan is an endothelial receptor antagonist (ERA) indicated for the treatment of Pulmonary arterial hypertension (PAH). The aim of the present study involves the development of controlled release tablets of bosentan1. The tablets were prepared to release the drug for a prolong period of time within the GIT, to enhance the bioavailability, to minimize the dosing frequency, and to improve the patient compliance2. The tablets were formulated by using various polymers like hydroxyl propyl methyl cellulose, acacia and xanthum. The formulated tablets were evaluated3. The drug release from the optimized formulation (F7) was found to be the best after observing the results of dissolution rate and pre &post formulation studies4.